Asthma

Apogee Therapeutics, Inc. Announces Pricing of Upsized $420 Million Underwritten Public Offering

Retrieved on: 
Thursday, March 7, 2024
Attention, SAN, Apsis, Lexington Avenue, Jefferies Group, Prospectus, Suite, Telephone, Atopic dermatitis, Asthma, Sale, Exercise, Montgomery Street, Chronic obstructive pulmonary disease, Therapy, Madison Avenue, BofA Securities, Security (finance), Goldman Sachs, Jefferies

The aggregate gross proceeds to Apogee from the offering are expected to be approximately $420.0 million before deducting underwriting discounts and commissions and other offering expenses payable by Apogee, excluding any exercise of the underwriters’ option to purchase additional shares.

Key Points: 
  • The aggregate gross proceeds to Apogee from the offering are expected to be approximately $420.0 million before deducting underwriting discounts and commissions and other offering expenses payable by Apogee, excluding any exercise of the underwriters’ option to purchase additional shares.
  • The offering is expected to close on March 12, 2024, subject to the satisfaction of customary closing conditions.
  • In addition, Apogee has granted the underwriters a 30-day option to purchase up to an additional 1,016,128 shares of common stock at the public offering price, less underwriting discounts and commissions.
  • Jefferies, BofA Securities, Goldman Sachs & Co. LLC, TD Cowen and Stifel are acting as joint book-running managers for the offering.

RAPT Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results

Retrieved on: 
Thursday, March 7, 2024
SAN, Research, RAPT, Atopic dermatitis, Asthma, AACR, Inflammation, Consultant, Safety, Therapy, Patient, Cancer, Pharmaceutical industry

SOUTH SAN FRANCISCO, Calif., March 07, 2024 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based therapeutics company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in inflammatory diseases and oncology, today reported financial results for the fourth quarter and year ended December 31, 2023.

Key Points: 
  • SOUTH SAN FRANCISCO, Calif., March 07, 2024 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based therapeutics company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in inflammatory diseases and oncology, today reported financial results for the fourth quarter and year ended December 31, 2023.
  • Separately, our Phase 2 study of tivumecirnon in cancer is ongoing and we will be presenting an update at AACR in April.”
    Financial Results for the Fourth Quarter and the Year Ended December 31, 2023
    Fourth Quarter Ended December 31, 2023
    Net loss for the fourth quarter of 2023 was $30.9 million, compared to $23.0 million for the fourth quarter of 2022.
  • Research and development expenses for the fourth quarter of 2023 were $26.8 million, compared to $19.5 million for the same period in 2022.
  • General and administrative expenses for the fourth quarter of 2023 were $6.5 million, compared to $5.0 million for the same period in 2022.

DBV Technologies Reports Full Year 2023 Financial Results and Business Update

Retrieved on: 
Thursday, March 7, 2024
Vitesse, European Commission, Marketing, DBV Technologies, Blas, FDA, Form 10-K, File, Research and development, Language, Sale, BLA, Toddler, American College, Form, Financial statement, Safety, American depositary receipt, GAAP, Good news, Immunology, Administration, Net, Food, Asthma, DBV, Initiate, Development, Bank statement, Agreement, Editorial, Cryptocurrency

DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company focused on treatment options for food allergies and other immunologic conditions with significant unmet medical need, today reported financial results for the full year 2023.

Key Points: 
  • DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company focused on treatment options for food allergies and other immunologic conditions with significant unmet medical need, today reported financial results for the full year 2023.
  • Published EPITOPE results in the New England Journal of Medicine with an accompanying editorial, entitled, Good News for Toddlers with Peanut Allergy.
  • ET to discuss full year 2023 financial results and provide a business update.
  • The conference call may be accessed by dialing:
    A webcast of the call will also be available under "Events" in the Investors section of the DBV Technologies website: https://dbv-technologies.com/investor-overview/events .

ASLAN Pharmaceuticals Announces New Translational Data on Eblasakimab in COPD and Appoints Leading Respiratory Experts as Scientific Advisors

Retrieved on: 
Wednesday, March 6, 2024
Translational medicine, SAN, MD, Emergency medicine, Partnership, Atopic dermatitis, Asthma, Chronic obstructive pulmonary disease, Rutgers University, Formoterol, Associate, Patient, Disease, Constriction, Harvard Medical School, ASLN, Pharmaceutical industry

“I’m delighted to work with the ASLAN team on this exciting opportunity to evaluate development paths for eblasakimab in COPD, a Type 2-driven disease.

Key Points: 
  • “I’m delighted to work with the ASLAN team on this exciting opportunity to evaluate development paths for eblasakimab in COPD, a Type 2-driven disease.
  • In November 2023, ASLAN announced translational data from healthy donor tissue that suggested eblasakimab’s potential as a COPD therapeutic to inhibit Type 2 inflammation.
  • Further studies have been conducted using lung tissue from a COPD patient, comparing the same concentrations of eblasakimab and dupilumab.
  • Further translational data on eblasakimab in COPD will be submitted for publication at upcoming scientific congresses.

Apogee Therapeutics, Inc. Announces Proposed Underwritten Public Offering

Retrieved on: 
Tuesday, March 5, 2024
Attention, SAN, Apsis, Lexington Avenue, Jefferies Group, Suite, Telephone, Atopic dermatitis, Asthma, Sale, Montgomery Street, Chronic obstructive pulmonary disease, Therapy, Madison Avenue, BofA Securities, Security (finance), Goldman Sachs, Jefferies

In addition, Apogee expects to grant the underwriters a 30-day option to purchase up to an additional $52.5 million of shares of common stock at the public offering price, less underwriting discounts and commissions.

Key Points: 
  • In addition, Apogee expects to grant the underwriters a 30-day option to purchase up to an additional $52.5 million of shares of common stock at the public offering price, less underwriting discounts and commissions.
  • The proposed public offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed or as to the actual size or terms of the offering.
  • Jefferies, BofA Securities, Goldman Sachs & Co. LLC, TD Cowen, and Stifel are acting as joint book-running managers for the proposed offering.
  • This offering will be made only by means of a written prospectus.

Tiny Health, Pioneer of the First At-Home Baby Gut Microbiome Test, Aims to Address the Pediatric Chronic Conditions Crisis

Retrieved on: 
Tuesday, March 5, 2024
Food, Diabetes, Fungus, Tiny, General partnership, Physician, Obesity, Pediatrics, Asthma, Overalls, Parent, Parasitism, Allergy, Life, Risk, IRB, Constipation, Health, Bacteria, Virus, Mother, Infant, Dermatitis, ADHD, Child, Science, Archaea, Research, Immune system, Partnership, Birth control

The partnership enables Tiny Health to continue trailblazing the gut health testing category and avert the pediatric chronic conditions crisis.

Key Points: 
  • The partnership enables Tiny Health to continue trailblazing the gut health testing category and avert the pediatric chronic conditions crisis.
  • Families are facing a pediatric chronic conditions crisis, with increasing rates of eczema, asthma, diabetes, obesity, food allergies, ADHD, autoimmune diseases, and more.
  • I founded Tiny Health to bridge the gap in the market, help address the pediatric chronic conditions crisis, and empower families to take a proactive approach to their lifelong health.
  • Since its inception, Tiny Health has pioneered the family gut testing category including:
    Established the first, at-home gut microbiome test for babies.

Apogee Therapeutics Provides Pipeline Progress and Reports Fourth Quarter and Full Year 2023 Financial Results

Retrieved on: 
Tuesday, March 5, 2024
SQ, PD, Injection, I&I, Research, OX40L, Inflammation, Atopic dermatitis, Growth, Asthma, TARC, Chronic obstructive pulmonary disease, IPO, Interim, Safety, Therapy, Pharmacokinetics, Patient, Clinical trial, Half-life, G&A, Pharmaceutical industry

SAN FRANCISCO and WALTHAM, Mass., March 05, 2024 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc. (Nasdaq: APGE), a clinical-stage biotechnology company advancing differentiated biologics for the treatment of atopic dermatitis (AD), chronic obstructive pulmonary disease (COPD), asthma and other inflammatory and immunology (I&I) indications, today reported pipeline highlights and fourth quarter and full year 2023 financial results.

Key Points: 
  • “2023 was a momentous year for Apogee with the completion of a successful IPO, initiation of our first clinical program of APG777 in healthy volunteers and the nomination of our second pipeline candidate, APG808,” said Michael Henderson, M.D., Chief Executive Officer of Apogee.
  • Cash Position: Cash, cash equivalents and marketable securities were $395.5 million as of December 31, 2023, compared to $151.9 million as of December 31, 2022.
  • Based on current operating plans, Apogee expects its existing cash, cash equivalents and marketable securities will enable the company to fund its operating expenses into 4Q 2026.
  • Net loss increased primarily as a result of higher R&D and G&A operating expenses as described above, partially offset by higher interest income.

Apogee Announces Positive Interim Results from Phase 1 Healthy Volunteer Trial for APG777, its Novel Half-Life Extended Anti-IL-13 Antibody for the Treatment for Atopic Dermatitis and Other Inflammatory Diseases, Exceeding its Trial Objectives Ahead of Sc

Retrieved on: 
Tuesday, March 5, 2024
Paragon, Well, SAD, PD, Injection, I&I, Waldman, Headache, Inflammation, Quality of life, Management, Atopic dermatitis, Asthma, TARC, AUC, Volunteering, Cmax, Chronic obstructive pulmonary disease, Outline of health sciences, Safety, Biomarker, Therapy, CQD, Chronic pain, Immunology, IGA, Webcast, Sleep, Patient, MPH, Half-life, Serum, Pharmaceutical industry

Based on these data, the company plans to initiate a randomized, placebo-controlled, Phase 2 clinical trial in patients with moderate-to-severe AD in the first half of 2024 ahead of schedule.

Key Points: 
  • Based on these data, the company plans to initiate a randomized, placebo-controlled, Phase 2 clinical trial in patients with moderate-to-severe AD in the first half of 2024 ahead of schedule.
  • At Apogee, we refuse to stop at good enough and are dedicated to advancing innovative solutions for patients.
  • The Phase 1 trial is a first-in-human, randomized, double-blind, placebo-controlled study designed to evaluate safety and PK of APG777 in healthy volunteers.
  • A live webcast of the call will be available on the Investor Relations page of Apogee’s website at https://investors.apogeetherapeutics.com/news-events/events .

Apogee to Host Conference Call and Webcast to Report Interim Results from Phase 1 Healthy Volunteer Trial for APG777, its Novel Half-Life Extended Anti-IL-13 Antibody for the Treatment for Atopic Dermatitis and Other Inflammatory Diseases on March 5, 2024

Retrieved on: 
Monday, March 4, 2024
Chronic obstructive pulmonary disease, Atopic dermatitis, SAN, Asthma, I&I, Therapy, Webcast

(Nasdaq: APGE), a clinical-stage biotechnology company advancing differentiated biologics for the treatment of atopic dermatitis, chronic obstructive pulmonary disease, asthma and other inflammatory and immunology (I&I) indications, today announced it will report interim results from the Phase 1 APG777 healthy volunteer trial on Tuesday, March 5, 2024.

Key Points: 
  • (Nasdaq: APGE), a clinical-stage biotechnology company advancing differentiated biologics for the treatment of atopic dermatitis, chronic obstructive pulmonary disease, asthma and other inflammatory and immunology (I&I) indications, today announced it will report interim results from the Phase 1 APG777 healthy volunteer trial on Tuesday, March 5, 2024.
  • Following the announcement, the Company will host a conference call and webcast at 7:00am ET to discuss the results.
  • To access the live and archived webcast, please visit the Investor Relations page of Apogee’s website at https://investors.apogeetherapeutics.com/news-events/events .
  • The archived webcast will be available for a limited time on the Company’s website.

ARS Pharmaceuticals announces neffy® meets primary endpoints and shows rapid symptom control in Phase 2 urticaria clinical study

Retrieved on: 
Monday, February 26, 2024
SAN, Incidence, The Study, AAAAI, Caregiver, Angioedema, Histamine, Principal, ARS, FDA, Quality of life, Anaphylaxis, Body surface area, Data, Convention center, Skin, Safety, Joint task force, Allergy, Patient, Flare, Data analysis, CSU, Erythema, Pediatrics, Asthma, Adrenaline, Itch, American Academy, Pharmaceutical industry

Urticaria is a skin disorder that causes itchy hives and/or angioedema; 50% of chronic urticaria cases1 are non-responsive to first-line antihistamine therapy.

Key Points: 
  • Urticaria is a skin disorder that causes itchy hives and/or angioedema; 50% of chronic urticaria cases1 are non-responsive to first-line antihistamine therapy.
  • “Urticaria is not only a standalone type I allergy disease, but also represents the most frequent symptom observed during type I allergic reactions including anaphylaxis.
  • neffy may provide episodic symptomatic relief of these acute flares or exacerbations to improve the quality of life of urticaria patients.
  • This would follow the anticipated FDA approval of neffy for allergic reactions (Type I) including anaphylaxis in the second half of 2024.